Relmada Therapeutics Inc

RLMD

Company Profile

  • Business description

    Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

  • Contact

    2222 Ponce de Leon Boulevard
    Floor 3
    Coral GablesFL33134
    USA

    T: +1 786 629-1376

    E: [email protected]

    https://www.relmada.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    17

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,777.9050.80-0.58%
CAC 407,862.9096.191.24%
DAX 4024,486.19279.281.15%
Dow JONES (US)44,240.76165.60-0.37%
FTSE 1008,881.1126.930.30%
HKSE23,892.32255.75-1.06%
NASDAQ20,418.465.950.03%
Nikkei 22539,821.28132.470.33%
NZX 50 Index12,768.6190.41-0.70%
S&P 5006,225.524.46-0.07%
S&P/ASX 2008,538.6052.10-0.61%
SSE Composite Index3,493.054.43-0.13%

Market Movers